company_name,company_ticker,company_lei,company_cik,year,quarter,start_date,end_date,filing_date,parent,tag,financial_name,factor,balance,unit,value
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 17:01:41+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1617000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 17:01:41+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,3563000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 17:01:41+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,5180000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 17:01:41+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-5180000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 17:01:41+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,26000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 17:01:41+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,26000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 17:01:41+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-5154000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 17:01:41+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 17:01:41+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-5154000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 17:01:41+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-5154000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 17:01:41+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-5154000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 17:01:41+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,57300000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 17:01:41+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.09
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 17:01:41+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,57300000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 17:01:41+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.09
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 17:01:41+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,58426995.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2010.0,Q2,2010-04-01,2010-06-30,2011-08-08 17:01:41+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.09
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2010.0,Q3,2010-07-01,2010-09-30,2011-11-04 17:01:51+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1710000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2010.0,Q3,2010-07-01,2010-09-30,2011-11-04 17:01:51+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4223000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2010.0,Q3,2010-07-01,2010-09-30,2011-11-04 17:01:51+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,5933000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2010.0,Q3,2010-07-01,2010-09-30,2011-11-04 17:01:51+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-5933000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2010.0,Q3,2010-07-01,2010-09-30,2011-11-04 17:01:51+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,85000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2010.0,Q3,2010-07-01,2010-09-30,2011-11-04 17:01:51+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,85000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2010.0,Q3,2010-07-01,2010-09-30,2011-11-04 17:01:51+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-5848000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2010.0,Q3,2010-07-01,2010-09-30,2011-11-04 17:01:51+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2010.0,Q3,2010-07-01,2010-09-30,2011-11-04 17:01:51+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-5848000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2010.0,Q3,2010-07-01,2010-09-30,2011-11-04 17:01:51+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-5848000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2010.0,Q3,2010-07-01,2010-09-30,2011-11-04 17:01:51+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-5848000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2010.0,Q3,2010-07-01,2010-09-30,2011-11-04 17:01:51+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,58500000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2010.0,Q3,2010-07-01,2010-09-30,2011-11-04 17:01:51+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.1
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2010.0,Q3,2010-07-01,2010-09-30,2011-11-04 17:01:51+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,58500000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2010.0,Q3,2010-07-01,2010-09-30,2011-11-04 17:01:51+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.1
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2010.0,Q3,2010-07-01,2010-09-30,2011-11-04 17:01:51+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,59324661.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2010.0,Q3,2010-07-01,2010-09-30,2011-11-04 17:01:51+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.1
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 10:24:29+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1598000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 10:24:29+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,4877000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 10:24:29+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,6475000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 10:24:29+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-6475000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 10:24:29+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,70000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 10:24:29+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,70000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 10:24:29+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-6405000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 10:24:29+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 10:24:29+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-6405000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 10:24:29+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-6405000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 10:24:29+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-6405000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 10:24:29+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,64100000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 10:24:29+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.1
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 10:24:29+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,64100000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 10:24:29+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.1
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 10:24:29+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,61549633.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q1,2011-01-01,2011-03-31,2012-05-09 10:24:29+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.1
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:30:33+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,5000000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:30:33+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,5000000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:30:33+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,5000000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:30:33+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1718000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:30:33+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,6500000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:30:33+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,8218000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:30:33+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-3218000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:30:33+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,122000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:30:33+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,122000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:30:33+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-3096000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:30:33+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:30:33+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-3096000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:30:33+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-3096000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:30:33+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-3096000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:30:33+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,61900000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:30:33+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.05
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:30:33+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,61900000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:30:33+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.05
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:30:33+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,66286615.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q2,2011-04-01,2011-06-30,2012-08-08 16:30:33+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.05
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 17:01:29+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1583000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 17:01:29+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8772000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 17:01:29+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,10355000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 17:01:29+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-10355000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 17:01:29+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,108000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 17:01:29+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,108000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 17:01:29+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-10247000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 17:01:29+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 17:01:29+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-10247000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 17:01:29+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-10247000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 17:01:29+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-10247000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 17:01:29+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,68300000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 17:01:29+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.15
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 17:01:29+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,68300000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 17:01:29+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.15
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 17:01:29+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,70483909.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q3,2011-07-01,2011-09-30,2012-11-08 17:01:29+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.15
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1838000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,6863000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q4,2011-10-01,2011-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,8701000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q4,2011-10-01,2011-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-8701000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q4,2011-10-01,2011-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,80000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q4,2011-10-01,2011-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,80000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q4,2011-10-01,2011-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-8621000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q4,2011-10-01,2011-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-8621000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q4,2011-10-01,2011-12-31,,netincome,netincomediscontinued,Net Income / (Loss) Discontinued Operations,+,credit,usd,246000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q4,2011-10-01,2011-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-8375000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q4,2011-10-01,2011-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-8375000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q4,2011-10-01,2011-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,67000000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q4,2011-10-01,2011-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.12
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q4,2011-10-01,2011-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,67000000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q4,2011-10-01,2011-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.12
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q4,2011-10-01,2011-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,67370354.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2011.0,Q4,2011-10-01,2011-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.12
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:36:49+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1776000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:36:49+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7400000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:36:49+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,9176000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:36:49+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-9176000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:36:49+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,62000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:36:49+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,62000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:36:49+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-9114000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:36:49+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:36:49+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-9114000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:36:49+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-9114000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:36:49+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-9114000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:36:49+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,70100000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:36:49+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.13
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:36:49+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,70100000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:36:49+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.13
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:36:49+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,71225006.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2012.0,Q1,2012-01-01,2012-03-31,2013-05-08 16:36:49+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.13
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:04:45+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1900000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:04:45+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,3799000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:04:45+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,5699000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:04:45+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-5699000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:04:45+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,1556000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:04:45+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,1556000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:04:45+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-4143000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:04:45+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:04:45+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-4143000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:04:45+00:00,netincome,extraordinaryincome,"Extraordinary Income / (Loss), net",+,credit,usd,2639000.04
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:04:45+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-1504000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:04:45+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-1504000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:04:45+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,18800000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:04:45+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.08
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:04:45+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,18800000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:04:45+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.08
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:04:45+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,71466740.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2012.0,Q2,2012-04-01,2012-06-30,2013-08-02 16:04:45+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.08
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2012.0,Q3,2012-07-01,2012-09-30,2013-11-04 17:01:51+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,1597000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2012.0,Q3,2012-07-01,2012-09-30,2013-11-04 17:01:51+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,3929000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2012.0,Q3,2012-07-01,2012-09-30,2013-11-04 17:01:51+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,5526000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2012.0,Q3,2012-07-01,2012-09-30,2013-11-04 17:01:51+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-5526000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2012.0,Q3,2012-07-01,2012-09-30,2013-11-04 17:01:51+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,51000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2012.0,Q3,2012-07-01,2012-09-30,2013-11-04 17:01:51+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,51000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2012.0,Q3,2012-07-01,2012-09-30,2013-11-04 17:01:51+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-5475000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2012.0,Q3,2012-07-01,2012-09-30,2013-11-04 17:01:51+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2012.0,Q3,2012-07-01,2012-09-30,2013-11-04 17:01:51+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-5475000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2012.0,Q3,2012-07-01,2012-09-30,2013-11-04 17:01:51+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-5475000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2012.0,Q3,2012-07-01,2012-09-30,2013-11-04 17:01:51+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-5475000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2012.0,Q3,2012-07-01,2012-09-30,2013-11-04 17:01:51+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,68400000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2012.0,Q3,2012-07-01,2012-09-30,2013-11-04 17:01:51+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.08
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2012.0,Q3,2012-07-01,2012-09-30,2013-11-04 17:01:51+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,68400000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2012.0,Q3,2012-07-01,2012-09-30,2013-11-04 17:01:51+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.08
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2012.0,Q3,2012-07-01,2012-09-30,2013-11-04 17:01:51+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,71910817.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2012.0,Q3,2012-07-01,2012-09-30,2013-11-04 17:01:51+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.08
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 16:02:53+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,7000000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 16:02:53+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,7000000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 16:02:53+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,7000000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 16:02:53+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,2728000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 16:02:53+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,6430000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 16:02:53+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,9158000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 16:02:53+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-2158000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 16:02:53+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,103000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 16:02:53+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,103000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 16:02:53+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-2055000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 16:02:53+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 16:02:53+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-2055000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 16:02:53+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-2055000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 16:02:53+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-2055000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 16:02:53+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,68500000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 16:02:53+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.03
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 16:02:53+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,68500000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 16:02:53+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.03
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 16:02:53+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,77990094.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q1,2013-01-01,2013-03-31,2014-05-08 16:02:53+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.03
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 17:03:19+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,4277000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 17:03:19+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7177000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 17:03:19+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,11454000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 17:03:19+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-11454000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 17:03:19+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,96000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 17:03:19+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,96000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 17:03:19+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-11358000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 17:03:19+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 17:03:19+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-11358000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 17:03:19+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-11358000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 17:03:19+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-11358000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 17:03:19+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,81100000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 17:03:19+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.14
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 17:03:19+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,81100000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 17:03:19+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.14
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 17:03:19+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,81739731.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q2,2013-04-01,2013-06-30,2014-08-07 17:03:19+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.14
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 17:05:20+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,5062000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 17:05:20+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,10670000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 17:05:20+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,15732000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 17:05:20+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-15732000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 17:05:20+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,81000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 17:05:20+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,81000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 17:05:20+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-15651000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 17:05:20+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 17:05:20+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-15651000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 17:05:20+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-15651000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 17:05:20+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-15651000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 17:05:20+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,82400000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 17:05:20+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.19
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 17:05:20+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,82400000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 17:05:20+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.19
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 17:05:20+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,81823415.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q3,2013-07-01,2013-09-30,2014-11-06 17:05:20+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.19
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7282000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,10457000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q4,2013-10-01,2013-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,17739000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q4,2013-10-01,2013-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-17739000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q4,2013-10-01,2013-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,71000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q4,2013-10-01,2013-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,71000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q4,2013-10-01,2013-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-17668000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q4,2013-10-01,2013-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-17668000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q4,2013-10-01,2013-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-17668000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q4,2013-10-01,2013-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-17668000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q4,2013-10-01,2013-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,80600000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q4,2013-10-01,2013-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.22
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q4,2013-10-01,2013-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,80600000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q4,2013-10-01,2013-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.22
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q4,2013-10-01,2013-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,81009561.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2013.0,Q4,2013-10-01,2013-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.22
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:34:59+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,10000000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:34:59+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,10000000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:34:59+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,10000000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:34:59+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,7292000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:34:59+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,16359000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:34:59+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,23651000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:34:59+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-13651000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:34:59+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,121000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:34:59+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,121000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:34:59+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-13530000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:34:59+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-13530000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:34:59+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-13530000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:34:59+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-13530000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:34:59+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,90200000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:34:59+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.15
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:34:59+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,90200000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:34:59+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.15
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:34:59+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,88517437.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q1,2014-01-01,2014-03-31,2015-05-04 16:34:59+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.15
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 17:02:24+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,12268000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 17:02:24+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,10275000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 17:02:24+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,22543000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 17:02:24+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-22543000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 17:02:24+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,129000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 17:02:24+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,129000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 17:02:24+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-22414000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 17:02:24+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-22414000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 17:02:24+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-22414000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 17:02:24+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-22414000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 17:02:24+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,93400000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 17:02:24+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.24
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 17:02:24+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,93400000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 17:02:24+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.24
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 17:02:24+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,91516606.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q2,2014-04-01,2014-06-30,2015-08-06 17:02:24+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.24
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q3,2014-07-01,2014-09-30,2015-10-29 17:16:29+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,256000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q3,2014-07-01,2014-09-30,2015-10-29 17:16:29+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,256000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q3,2014-07-01,2014-09-30,2015-10-29 17:16:29+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,154000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q3,2014-07-01,2014-09-30,2015-10-29 17:16:29+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,154000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q3,2014-07-01,2014-09-30,2015-10-29 17:16:29+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,102000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q3,2014-07-01,2014-09-30,2015-10-29 17:16:29+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,16447000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q3,2014-07-01,2014-09-30,2015-10-29 17:16:29+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,19053000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q3,2014-07-01,2014-09-30,2015-10-29 17:16:29+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,35500000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q3,2014-07-01,2014-09-30,2015-10-29 17:16:29+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-35398000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q3,2014-07-01,2014-09-30,2015-10-29 17:16:29+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,109000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q3,2014-07-01,2014-09-30,2015-10-29 17:16:29+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,109000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q3,2014-07-01,2014-09-30,2015-10-29 17:16:29+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-35289000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q3,2014-07-01,2014-09-30,2015-10-29 17:16:29+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-35289000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q3,2014-07-01,2014-09-30,2015-10-29 17:16:29+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-35289000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q3,2014-07-01,2014-09-30,2015-10-29 17:16:29+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-35289000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q3,2014-07-01,2014-09-30,2015-10-29 17:16:29+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,92900000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q3,2014-07-01,2014-09-30,2015-10-29 17:16:29+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.38
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q3,2014-07-01,2014-09-30,2015-10-29 17:16:29+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,92900000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q3,2014-07-01,2014-09-30,2015-10-29 17:16:29+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.38
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q3,2014-07-01,2014-09-30,2015-10-29 17:16:29+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,91846588.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q3,2014-07-01,2014-09-30,2015-10-29 17:16:29+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.38
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q4,2014-10-01,2014-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,74000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q4,2014-10-01,2014-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,74000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q4,2014-10-01,2014-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,-154000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q4,2014-10-01,2014-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,-154000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,228000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,34050000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,5815000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q4,2014-10-01,2014-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,39865000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q4,2014-10-01,2014-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-39637000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q4,2014-10-01,2014-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,52000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q4,2014-10-01,2014-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,52000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q4,2014-10-01,2014-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-39585000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q4,2014-10-01,2014-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,700000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q4,2014-10-01,2014-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-40285000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q4,2014-10-01,2014-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-40285000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q4,2014-10-01,2014-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-40285000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q4,2014-10-01,2014-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,90700000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q4,2014-10-01,2014-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.46
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q4,2014-10-01,2014-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,90700000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q4,2014-10-01,2014-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.46
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q4,2014-10-01,2014-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,91000902.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2014.0,Q4,2014-10-01,2014-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.46
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q1,2015-01-01,2015-03-31,2016-04-28 16:05:41+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,1175000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q1,2015-01-01,2015-03-31,2016-04-28 16:05:41+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,1175000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q1,2015-01-01,2015-03-31,2016-04-28 16:05:41+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,528000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q1,2015-01-01,2015-03-31,2016-04-28 16:05:41+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,528000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q1,2015-01-01,2015-03-31,2016-04-28 16:05:41+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,647000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q1,2015-01-01,2015-03-31,2016-04-28 16:05:41+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,18880000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q1,2015-01-01,2015-03-31,2016-04-28 16:05:41+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,9591000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q1,2015-01-01,2015-03-31,2016-04-28 16:05:41+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,28471000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q1,2015-01-01,2015-03-31,2016-04-28 16:05:41+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-27824000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q1,2015-01-01,2015-03-31,2016-04-28 16:05:41+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,107000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q1,2015-01-01,2015-03-31,2016-04-28 16:05:41+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,107000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q1,2015-01-01,2015-03-31,2016-04-28 16:05:41+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-27717000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q1,2015-01-01,2015-03-31,2016-04-28 16:05:41+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,22000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q1,2015-01-01,2015-03-31,2016-04-28 16:05:41+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-27739000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q1,2015-01-01,2015-03-31,2016-04-28 16:05:41+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-27739000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q1,2015-01-01,2015-03-31,2016-04-28 16:05:41+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-27739000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q1,2015-01-01,2015-03-31,2016-04-28 16:05:41+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,99100000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q1,2015-01-01,2015-03-31,2016-04-28 16:05:41+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.28
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q1,2015-01-01,2015-03-31,2016-04-28 16:05:41+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,99100000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q1,2015-01-01,2015-03-31,2016-04-28 16:05:41+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.28
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q1,2015-01-01,2015-03-31,2016-04-28 16:05:41+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,100553490.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q1,2015-01-01,2015-03-31,2016-04-28 16:05:41+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.28
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 17:31:30+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,2514000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 17:31:30+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,2514000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 17:31:30+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,757000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 17:31:30+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,757000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 17:31:30+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,1757000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 17:31:30+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,20762000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 17:31:30+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7963000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 17:31:30+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,28725000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 17:31:30+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-26968000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 17:31:30+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,114000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 17:31:30+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,114000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 17:31:30+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-26854000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 17:31:30+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,23000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 17:31:30+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-26877000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 17:31:30+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-26877000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 17:31:30+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-26877000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 17:31:30+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,103400000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 17:31:30+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.26
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 17:31:30+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,103400000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 17:31:30+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.26
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 17:31:30+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,104564971.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q2,2015-04-01,2015-06-30,2016-08-05 17:31:30+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.26
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 07:18:58+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,4208000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 07:18:58+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,4208000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 07:18:58+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,3676000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 07:18:58+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,3676000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 07:18:58+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,532000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 07:18:58+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,20205000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 07:18:58+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,11150000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 07:18:58+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,31355000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 07:18:58+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-30823000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 07:18:58+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,100000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 07:18:58+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,100000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 07:18:58+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-30723000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 07:18:58+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,22000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 07:18:58+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-30745000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 07:18:58+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-30745000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 07:18:58+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-30745000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 07:18:58+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,106000000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 07:18:58+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.29
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 07:18:58+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,106000000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 07:18:58+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.29
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 07:18:58+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,105205170.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q3,2015-07-01,2015-09-30,2016-11-09 07:18:58+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.29
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q4,2015-10-01,2015-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,3659000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q4,2015-10-01,2015-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,3659000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q4,2015-10-01,2015-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,-441000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q4,2015-10-01,2015-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,-441000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,4100000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,21563000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7990000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q4,2015-10-01,2015-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,29553000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-25453000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,11357000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q4,2015-10-01,2015-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-951000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q4,2015-10-01,2015-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-12308000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-37761000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q4,2015-10-01,2015-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,23000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q4,2015-10-01,2015-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-37784000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q4,2015-10-01,2015-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-37784000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q4,2015-10-01,2015-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-37784000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q4,2015-10-01,2015-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,103500000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q4,2015-10-01,2015-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.36
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q4,2015-10-01,2015-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,103500000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q4,2015-10-01,2015-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.36
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q4,2015-10-01,2015-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,103898399.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2015.0,Q4,2015-10-01,2015-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.36
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:36:34+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,6825000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:36:34+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,6825000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:36:34+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,1797000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:36:34+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,1797000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:36:34+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,5028000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:36:34+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,20809000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:36:34+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7616000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:36:34+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,28425000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:36:34+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-23397000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:36:34+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,15748000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:36:34+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-1799000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:36:34+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-17547000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:36:34+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-40944000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:36:34+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,20000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:36:34+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-40964000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:36:34+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-40964000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:36:34+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-40964000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:36:34+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,105000000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:36:34+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.39
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:36:34+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,105000000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:36:34+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.39
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:36:34+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,105649571.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q1,2016-01-01,2016-03-31,2017-05-04 16:36:34+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.39
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q2,2016-04-01,2016-06-30,2017-07-27 07:20:19+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,9288000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q2,2016-04-01,2016-06-30,2017-07-27 07:20:19+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,9288000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q2,2016-04-01,2016-06-30,2017-07-27 07:20:19+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,5704000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q2,2016-04-01,2016-06-30,2017-07-27 07:20:19+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,5704000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q2,2016-04-01,2016-06-30,2017-07-27 07:20:19+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,3584000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q2,2016-04-01,2016-06-30,2017-07-27 07:20:19+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,20188000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q2,2016-04-01,2016-06-30,2017-07-27 07:20:19+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7029000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q2,2016-04-01,2016-06-30,2017-07-27 07:20:19+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,27217000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q2,2016-04-01,2016-06-30,2017-07-27 07:20:19+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-23633000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q2,2016-04-01,2016-06-30,2017-07-27 07:20:19+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,18500000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q2,2016-04-01,2016-06-30,2017-07-27 07:20:19+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-2519000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q2,2016-04-01,2016-06-30,2017-07-27 07:20:19+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-21019000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q2,2016-04-01,2016-06-30,2017-07-27 07:20:19+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-44631000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q2,2016-04-01,2016-06-30,2017-07-27 07:20:19+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,20000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q2,2016-04-01,2016-06-30,2017-07-27 07:20:19+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-44651000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q2,2016-04-01,2016-06-30,2017-07-27 07:20:19+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-44651000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q2,2016-04-01,2016-06-30,2017-07-27 07:20:19+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-44651000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q2,2016-04-01,2016-06-30,2017-07-27 07:20:19+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,106300000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q2,2016-04-01,2016-06-30,2017-07-27 07:20:19+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.42
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q2,2016-04-01,2016-06-30,2017-07-27 07:20:19+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,106300000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q2,2016-04-01,2016-06-30,2017-07-27 07:20:19+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.42
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q2,2016-04-01,2016-06-30,2017-07-27 07:20:19+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,105842030.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q2,2016-04-01,2016-06-30,2017-07-27 07:20:19+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.42
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 08:50:09+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,6337000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 08:50:09+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,6337000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 08:50:09+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,18968000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 08:50:09+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,18968000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 08:50:09+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,-12631000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 08:50:09+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,20521000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 08:50:09+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8674000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 08:50:09+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,29195000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 08:50:09+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-41826000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 08:50:09+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,0.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 08:50:09+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,150000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 08:50:09+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,150000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 08:50:09+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-41676000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 08:50:09+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,20000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 08:50:09+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-41696000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 08:50:09+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-41696000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 08:50:09+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-41696000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 08:50:09+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,106900000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 08:50:09+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.39
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 08:50:09+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,106900000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 08:50:09+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.39
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 08:50:09+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,105924106.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q3,2016-07-01,2016-09-30,2017-11-07 08:50:09+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.39
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q4,2016-10-01,2016-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,6647000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q4,2016-10-01,2016-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,6647000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q4,2016-10-01,2016-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,11334000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q4,2016-10-01,2016-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,11334000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,-4687000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,23035000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,6185000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q4,2016-10-01,2016-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,29220000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-33907000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,-21000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q4,2016-10-01,2016-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,143000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q4,2016-10-01,2016-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,164000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-33764000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q4,2016-10-01,2016-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,40000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q4,2016-10-01,2016-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-33804000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q4,2016-10-01,2016-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-33784000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q4,2016-10-01,2016-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-33784000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q4,2016-10-01,2016-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,106000000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q4,2016-10-01,2016-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.32
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q4,2016-10-01,2016-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,106000000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q4,2016-10-01,2016-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.32
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q4,2016-10-01,2016-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,105845121.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2016.0,Q4,2016-10-01,2016-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.32
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:23:03+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,11819000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:23:03+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,11819000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:23:03+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,5062000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:23:03+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,5062000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:23:03+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,6757000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:23:03+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,23103000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:23:03+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,6764000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:23:03+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,29867000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:23:03+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-23110000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:23:03+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,114000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:23:03+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,114000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:23:03+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-22996000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:23:03+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,20000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:23:03+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-23016000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:23:03+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-23016000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:23:03+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-23016000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:23:03+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,109600000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:23:03+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.21
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:23:03+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,109600000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:23:03+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.21
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:23:03+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,107071634.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q1,2017-01-01,2017-03-31,2018-05-10 16:23:03+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.21
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 16:15:44+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,15116000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 16:15:44+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,15116000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 16:15:44+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,4979000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 16:15:44+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,4979000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 16:15:44+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,10137000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 16:15:44+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,24986000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 16:15:44+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,9012000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 16:15:44+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,33998000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 16:15:44+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-23850000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 16:15:44+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,62965000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 16:15:44+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,338000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 16:15:44+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-62627000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 16:15:44+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-86477000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 16:15:44+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,20000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 16:15:44+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-86497000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 16:15:44+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-86497000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 16:15:44+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-86497000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 16:15:44+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,112300000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 16:15:44+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.77
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 16:15:44+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,112300000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 16:15:44+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.77
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 16:15:44+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,112590188.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q2,2017-04-01,2017-06-30,2018-08-09 16:15:44+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.77
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:32:07+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,14996000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:32:07+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,14996000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:32:07+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,6694000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:32:07+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,6694000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:32:07+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,8302000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:32:07+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,22746000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:32:07+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,9275000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:32:07+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,32021000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:32:07+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-23719000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:32:07+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,0.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:32:07+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,241000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:32:07+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,241000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:32:07+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-23478000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:32:07+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,20000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:32:07+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-23498000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:32:07+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-23498000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:32:07+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-23498000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:32:07+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,117500000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:32:07+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.2
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:32:07+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,117500000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:32:07+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.2
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:32:07+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,118992825.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q3,2017-07-01,2017-09-30,2018-11-08 17:32:07+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.2
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q4,2017-10-01,2017-12-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,15634000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q4,2017-10-01,2017-12-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,15634000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q4,2017-10-01,2017-12-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,5220000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q4,2017-10-01,2017-12-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,5220000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,10414000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,28787000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,12628000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q4,2017-10-01,2017-12-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,41415000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q4,2017-10-01,2017-12-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-31012000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q4,2017-10-01,2017-12-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,288000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q4,2017-10-01,2017-12-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,288000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q4,2017-10-01,2017-12-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-30724000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q4,2017-10-01,2017-12-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-260000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q4,2017-10-01,2017-12-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-30464000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q4,2017-10-01,2017-12-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-30429000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q4,2017-10-01,2017-12-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-30429000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q4,2017-10-01,2017-12-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,114300000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q4,2017-10-01,2017-12-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.25
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q4,2017-10-01,2017-12-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,114300000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q4,2017-10-01,2017-12-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.25
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q4,2017-10-01,2017-12-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,114507668.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2017.0,Q4,2017-10-01,2017-12-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.25
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q1,2018-01-01,2018-03-31,2018-05-10 16:23:03+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,21751000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q1,2018-01-01,2018-03-31,2018-05-10 16:23:03+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,21751000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q1,2018-01-01,2018-03-31,2018-05-10 16:23:03+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,10278000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q1,2018-01-01,2018-03-31,2018-05-10 16:23:03+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,10278000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q1,2018-01-01,2018-03-31,2018-05-10 16:23:03+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,11473000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q1,2018-01-01,2018-03-31,2018-05-10 16:23:03+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,25837000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q1,2018-01-01,2018-03-31,2018-05-10 16:23:03+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8388000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q1,2018-01-01,2018-03-31,2018-05-10 16:23:03+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,34225000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q1,2018-01-01,2018-03-31,2018-05-10 16:23:03+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-22752000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q1,2018-01-01,2018-03-31,2018-05-10 16:23:03+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,222000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q1,2018-01-01,2018-03-31,2018-05-10 16:23:03+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,222000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q1,2018-01-01,2018-03-31,2018-05-10 16:23:03+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-22530000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q1,2018-01-01,2018-03-31,2018-05-10 16:23:03+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-634000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q1,2018-01-01,2018-03-31,2018-05-10 16:23:03+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-21896000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q1,2018-01-01,2018-03-31,2018-05-10 16:23:03+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-21896000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q1,2018-01-01,2018-03-31,2018-05-10 16:23:03+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-21896000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q1,2018-01-01,2018-03-31,2018-05-10 16:23:03+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,121600000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q1,2018-01-01,2018-03-31,2018-05-10 16:23:03+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.18
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q1,2018-01-01,2018-03-31,2018-05-10 16:23:03+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,121600000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q1,2018-01-01,2018-03-31,2018-05-10 16:23:03+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.18
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q1,2018-01-01,2018-03-31,2018-05-10 16:23:03+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,119844320.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q1,2018-01-01,2018-03-31,2018-05-10 16:23:03+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.18
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q2,2018-04-01,2018-06-30,2018-08-09 16:15:44+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,25749000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q2,2018-04-01,2018-06-30,2018-08-09 16:15:44+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,25749000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q2,2018-04-01,2018-06-30,2018-08-09 16:15:44+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,8415000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q2,2018-04-01,2018-06-30,2018-08-09 16:15:44+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,8415000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q2,2018-04-01,2018-06-30,2018-08-09 16:15:44+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,17334000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q2,2018-04-01,2018-06-30,2018-08-09 16:15:44+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,28711000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q2,2018-04-01,2018-06-30,2018-08-09 16:15:44+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8774000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q2,2018-04-01,2018-06-30,2018-08-09 16:15:44+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,37485000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q2,2018-04-01,2018-06-30,2018-08-09 16:15:44+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-20151000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q2,2018-04-01,2018-06-30,2018-08-09 16:15:44+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,1316000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q2,2018-04-01,2018-06-30,2018-08-09 16:15:44+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-51000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q2,2018-04-01,2018-06-30,2018-08-09 16:15:44+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1367000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q2,2018-04-01,2018-06-30,2018-08-09 16:15:44+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-21518000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q2,2018-04-01,2018-06-30,2018-08-09 16:15:44+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q2,2018-04-01,2018-06-30,2018-08-09 16:15:44+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-21518000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q2,2018-04-01,2018-06-30,2018-08-09 16:15:44+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-21518000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q2,2018-04-01,2018-06-30,2018-08-09 16:15:44+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-21518000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q2,2018-04-01,2018-06-30,2018-08-09 16:15:44+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,119500000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q2,2018-04-01,2018-06-30,2018-08-09 16:15:44+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.18
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q2,2018-04-01,2018-06-30,2018-08-09 16:15:44+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,119500000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q2,2018-04-01,2018-06-30,2018-08-09 16:15:44+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.18
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q2,2018-04-01,2018-06-30,2018-08-09 16:15:44+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,120451534.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q2,2018-04-01,2018-06-30,2018-08-09 16:15:44+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.18
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q3,2018-07-01,2018-09-30,2018-11-08 17:32:07+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,28036000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q3,2018-07-01,2018-09-30,2018-11-08 17:32:07+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,28036000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q3,2018-07-01,2018-09-30,2018-11-08 17:32:07+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,8373000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q3,2018-07-01,2018-09-30,2018-11-08 17:32:07+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,8373000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q3,2018-07-01,2018-09-30,2018-11-08 17:32:07+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,19663000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q3,2018-07-01,2018-09-30,2018-11-08 17:32:07+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,26453000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q3,2018-07-01,2018-09-30,2018-11-08 17:32:07+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7896000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q3,2018-07-01,2018-09-30,2018-11-08 17:32:07+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,34349000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q3,2018-07-01,2018-09-30,2018-11-08 17:32:07+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-14686000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q3,2018-07-01,2018-09-30,2018-11-08 17:32:07+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,2214000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q3,2018-07-01,2018-09-30,2018-11-08 17:32:07+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-95000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q3,2018-07-01,2018-09-30,2018-11-08 17:32:07+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2309000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q3,2018-07-01,2018-09-30,2018-11-08 17:32:07+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-16995000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q3,2018-07-01,2018-09-30,2018-11-08 17:32:07+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,0.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q3,2018-07-01,2018-09-30,2018-11-08 17:32:07+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-16995000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q3,2018-07-01,2018-09-30,2018-11-08 17:32:07+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-16995000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q3,2018-07-01,2018-09-30,2018-11-08 17:32:07+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-16995000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q3,2018-07-01,2018-09-30,2018-11-08 17:32:07+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,121400000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q3,2018-07-01,2018-09-30,2018-11-08 17:32:07+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.14
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q3,2018-07-01,2018-09-30,2018-11-08 17:32:07+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,121400000.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q3,2018-07-01,2018-09-30,2018-11-08 17:32:07+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.14
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q3,2018-07-01,2018-09-30,2018-11-08 17:32:07+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,120432827.0
Keryx Biopharmaceuticals Inc,KERX,,0001114220,2018.0,Q3,2018-07-01,2018-09-30,2018-11-08 17:32:07+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.14
